Sweden

Oncopeptides AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen

Lead Product(s): Melphalan Flufenamide,Dexamethasone

Therapeutic Area: Oncology Product Name: Melflufen

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The submission is based on the results from the pivotal phase 2 study HORIZON, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma (RRMM).

Oncopeptides AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients

Lead Product(s): Melphalan Flufenamide,Dexamethasone

Therapeutic Area: Oncology Product Name: Melflufen

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

The results support the NDA submission to the US FDA, for accelerated approval of melflufen of company's phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma.

Oncopeptides AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma

Lead Product(s): Melphalan Flufenamide,Dexamethasone

Therapeutic Area: Oncology Product Name: Melflufen

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

Melflufen is an investigational first-in-class anticancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in late stage clinical development for a potential treatment of patients with relapsed refractory multiple myeloma.

Oncopeptides AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Oncopeptides Announces Positive Results From OCEAN Study Between Melflufen & Pomalidomide In Patients With RRMM

Lead Product(s): Melphalan Flufenamide,Dexamethasone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

OCEAN is a randomized, comparative study between melflufen and pomalidomide in patients with relapsed refractory multiple myeloma. A recent analysis indicates that patients enrolled in the OCEAN-study continue treatment for a longer period of time than originally estimated.

Oncopeptides AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included

Lead Product(s): Melphalan Flufenamide,Dexamethasone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

OCEAN is a randomized, comparative study between melflufen and pomalidomide in patients with relapsed refractory multiple myeloma (RRMM).

Oncopeptides AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting

Lead Product(s): Melphalan Flufenamide,Dexamethasone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

One of the abstracts relates to the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple myeloma (RRMM) patients.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Oncopeptides AB

Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen

Oncopeptides AB

Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients

Oncopeptides AB

Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma

Oncopeptides AB

Oncopeptides Announces Positive Results From OCEAN Study Between Melflufen & Pomalidomide In Patients With RRMM

Oncopeptides AB

Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included

Oncopeptides AB

Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting